About Stonehaven, LLC Stonehaven is an industry leading global placement agent focused on hedge funds, private equity, real estate, venture capital, private placements, and long‐only strategies. Stonehaven’s platform serves as a nexus between select investment opportunities and the institutional investment community with a talented capital raising team and robust infrastructure. The Firm’s dynamic structure fosters an ever‐ evolving stable of distinctive managers to match the demand across the diverse investor community. Founded in 2001 by CEO David Frank, the Firm is entirely management owned, giving it complete independence to continue pursuing its entrepreneurial approach while maintaining the highest ethical and regulatory standards.
We are excited to announce that Simon Vine, Ph.D., Founder and CEO of Yesod Capital LLC has joined as an Affiliate Partner. Prior to founding Yesod Capital, Dr. Vine served in various positions for approximately 20 years within Alfa Bank, the top Russian non-state-owned bank. Most recently, Dr. Vine served as Co-Head of the Corporate Investment Bank (CIB) and an Executive Board Member, and prior to this role, Dr. Vine served as a Managing Director and Head of the Fixed Income and Derivatives Department at Alfa Bank. Prior to Alfa Bank, Dr. Vine served as a Senior Director in charge of derivatives for the Treasury Department within American Express Bank, Ltd. Prior to his role with American Express, Dr. Vine was a hedge fund manager at REFCO, Ltd. Prior to REFCO, Dr. Vine served as a Head of FX and Precious metals Derivatives for UBS, NY and before that as an Options trader in the Options Department within Société Générale Bank. Dr. Vine earned a Ph.D. in Economics from the Russian Presidential Academy of National Economy and Public Administration. He also earned an MBA in Finance with a focus in Accounting and International Banking from Columbia Business School. Dr. Vine also attended various executive training programs at INSEAD. Dr. Vine has published multiple books on finance, including one endorsed by Nassim Taleb. Dr. Vine is currently pursuing the Series 7 and 63 registrations with FINRA.